Research programme: CDK2/Cyclin A inhibitors - Genentech
Latest Information Update: 10 Mar 2008
Price :
$50 *
At a glance
- Originator Genentech
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Sep 2005 Preclinical trials in Cancer in USA (unspecified route)